NCT04643002
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol treatment 1 / 2 recruiting NCT06356571
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma treatment 2 not_yet_recruiting NCT04892264
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma treatment 1 / 2 completed NCT04956302
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma treatment 1 terminated NCT00082784
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms treatment 1 completed NCT04640779
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma treatment 1 recruiting NCT01689987
Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT02765854
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement treatment 2 active_not_recruiting NCT03502577
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma treatment 1 terminated NCT03256045
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma treatment 2 terminated NCT02948283
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia treatment 1 completed NCT03202628
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT00966693
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT04205409
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies treatment 2 active_not_recruiting NCT01605032
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 2 completed NCT03457142
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy treatment 2 active_not_recruiting NCT04407442
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab treatment 2 terminated NCT04850599
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT02095834
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT01794039
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide treatment 2 completed NCT01330173
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma treatment 1 completed NCT00789776
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer treatment 1 / 2 completed NCT03713294
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT03763162
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 active_not_recruiting NCT00793572
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma treatment 2 completed NCT01251172
RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 2 withdrawn NCT02119468
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma treatment 1 / 2 completed NCT03333746
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 terminated NCT04439214
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) treatment 2 completed NCT01085214
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma treatment 2 completed NCT04579523
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma treatment 1 not_yet_recruiting NCT05514990
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial treatment 1 / 2 recruiting NCT01936090
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 1 completed NCT04508790
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma treatment 2 recruiting NCT03701321
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 withdrawn NCT03710421
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma treatment 1 recruiting NCT03506802
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma treatment 1 withdrawn NCT01326702
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors treatment 1 / 2 completed NCT01989598
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT04439305
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) treatment 2 withdrawn NCT05411497
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma treatment 1 recruiting NCT05363111
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma treatment 1 recruiting NCT01903811
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma treatment 2 completed NCT03267888
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT01301807
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT01946152
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 terminated NCT02086552
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 2 completed NCT02509052
Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 / 2 completed NCT02506959
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma treatment 2 completed NCT03128359
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant supportive_care 2 completed NCT01503242
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 1 completed NCT03328936
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant treatment 2 withdrawn NCT01955434
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed NCT02109224
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection treatment 1 terminated NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial treatment 1 terminated NCT01028716
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 terminated NCT01163357
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma treatment 1 active_not_recruiting NCT01899326
Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant treatment Not Available terminated NCT03017820
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma treatment 1 recruiting NCT03829020
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma treatment 1 completed NCT01415882
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib treatment 2 active_not_recruiting NCT02514382
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT01533194
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT01646762
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 terminated NCT01008462
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia treatment 2 completed NCT05288062
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma treatment 2 active_not_recruiting NCT00445692
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma treatment 2 completed NCT03015792
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant treatment 1 / 2 terminated NCT04439240
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) treatment 2 completed NCT01372540
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia treatment 1 completed NCT04756401
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma treatment 2 recruiting NCT00105001
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT03338972
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma treatment 1 completed NCT05191472
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies treatment 2 terminated NCT02353468
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant treatment 2 terminated NCT03856112
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma treatment 1 / 2 withdrawn NCT02971410
Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma treatment 0 withdrawn NCT00450814
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma treatment 1 / 2 completed NCT04409314
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy Not Available Not Available completed NCT05312255
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma treatment Not Available recruiting NCT05391750
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma treatment 1 recruiting NCT01842308
Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma treatment 1 / 2 completed NCT00066638
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma treatment 2 completed